You have 9 free searches left this month | to do more

acalabrutinib

Acalabrutinib is a drug used to treat Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Acalabrutinib is being actively studied in 66 studies and prior, has been studied in 14.

Top SponsorsTop SitesTop Investigators
Acerta Pharma BVResearch SiteAustin I Kim
AstraZenecaM D Anderson Cancer CenterCarsten Utoft Niemann
M.D. Anderson Cancer CenterBeth Israel Deaconess Medical CenterCraig Moskowitz
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
  • Central Nervous System Lymphoma
  • Chapel Hill, North Carolina
  • +1 more
2022-03-24
Mar 24, 2022
W
Withdrawn
  • Chronic Lymphocytic Leukemia
  • CLL/SLL
  • Acalabrutinib
  • New York, New York
    Weill Cornell Medicine
2022-03-25
Mar 25, 2022
D
Recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
2022-02-02
Feb 2, 2022
U
Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
2021-08-04
Aug 4, 2021
D
Recruiting
  • Central Nervous System Lymphoma
  • +2 more
  • Acalabrutinib
  • Boston, Massachusetts
  • +1 more
2022-01-05
Jan 5, 2022
U
Recruiting
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • R-CHOP chemotherapy
  • Vancouver, British Columbia, Canada
  • +3 more
2022-03-17
Mar 17, 2022
W
Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-02
Feb 2, 2022
U
Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Rochester, New York
    University of Rochester
2022-02-07
Feb 7, 2022
W
Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-03-14
Mar 14, 2022
F
Recruiting
  • Recurrent Moderate-Severe Chronic Graft Versus Host Disease
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Acalabrutinib
  • Questionnaire Administration
  • Tampa, Florida
  • +3 more
2021-12-22
Dec 22, 2021
C
Recruiting
  • Autoimmune Hemolytic Anemia
  • +3 more
  • Acalabrutinib
  • Duarte, California
    City of Hope Medical Center
2022-03-09
Mar 9, 2022
S
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Seattle, Washington
    Swedish Cancer Institute
2021-03-01
Mar 1, 2021
M
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib
  • Obinutuzumab
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-18
Nov 18, 2021
J
Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Acalabrutinib
  • Los Angeles, California
  • +2 more
2022-03-17
Mar 17, 2022
F
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
N
Recruiting
  • Non-Hodgkin's Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
A
Completed
  • Hepatic Impairment
  • +2 more
  • acalabrutinib
  • Miami, Florida
  • +2 more
2021-08-16
Aug 16, 2021
J
Recruiting
  • Food Allergy
  • Food Allergy Peanut
  • Acalabrutinib
  • Baltimore, Maryland
    Johns Hopkins Bayview Medical Center
2021-12-30
Dec 30, 2021
U
Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Acalabrutinib
  • Axicabtagene Ciloleucel
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
N
Recruiting
  • Recurrent Follicular Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-12-16
Dec 16, 2021
J
Recruiting
  • IgM MGUS
  • +2 more
  • Boston, Massachusetts
  • +1 more
2022-02-16
Feb 16, 2022
M
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib
  • +4 more
  • Scottsdale, Arizona
  • +2 more
2021-08-19
Aug 19, 2021
S
Recruiting
  • Waldenstrom Macroglobulinemia
  • Acalabrutinib
  • +2 more
  • Vancouver, British Columbia, Canada
  • +3 more
2021-07-23
Jul 23, 2021